Mackay Shields LLC’s Audentes Therapeutics, Inc BOLD Stock Holding History

Mackay Shields LLC’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-50,894	Closed	-$3.05M	–	1561
2019 Q4	$3.05M	Buy	50,894 +5,400	+12%	+$203K	0.02%	704
2019 Q3	$1.28M	Buy	45,494 +5,700	+14%	+$195K	0.01%	1054
2019 Q2	$1.51M	Buy	39,794 +23,841	+149%	+$916K	0.01%	1012
2019 Q1	$622K	Buy	15,953 +3,500	+28%	+$100K	﹤0.01%	1131
2018 Q4	$265K	Sell	12,453 -1,347	-10%	-$34.8K	﹤0.01%	1270
2018 Q3	$546K	Buy	13,800 +2,800	+25%	+$104K	﹤0.01%	990
2018 Q2	$421K	Buy	+11,000	New	+$407K	﹤0.01%	1124

Mackay Shields LLC's BOLD Position: Q1 2020 in Review

Mackay Shields LLC sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 50,894 shares — an estimated $3.05M sold.

Mackay Shields LLC first reported a position in BOLD in Q2 2018 and held it in 7 quarters. The position peaked at $3.05M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Mackay Shields LLC reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Mackay Shields LLC sold 50,894 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $3.05M.
Mackay Shields LLC first reported a position in Audentes Therapeutics, Inc in Q2 2018 and held it in 7 quarters.
Mackay Shields LLC's Audentes Therapeutics, Inc position peaked at $3.05M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Mackay Shields LLC's 13F filing for Q1 2020, filed 8 May 2020.